@article{fernandez-banares_collagenous_2017,
	title = {Collagenous colitis: {Requirement} for high-dose budesonide as maintenance treatment},
	volume = {49},
	issn = {1878-3562},
	shorttitle = {Collagenous colitis},
	doi = {10.1016/j.dld.2017.03.026},
	abstract = {BACKGROUND: Controlled studies show high efficacy of budesonide in inducing short-term clinical remission in collagenous colitis (CC), but relapses are common after its withdrawal.
AIM: To evaluate the need for high-dose budesonide (≥6mg/d) to maintain clinical remission in CC.
METHODS: Analysis of a multicentre retrospective cohort of 75 patients with CC (62.3±1.5years; 85\% women) treated with budesonide in a clinical practice setting between 2013 and 2015. Frequency of budesonide (9mg/d) refractoriness and safety, and the need for high-dose budesonide to maintain clinical remission, were evaluated. Drugs used as budesonide-sparing, including azathioprine and mercaptopurine, were recorded. Logistic regression analysis was performed to evaluate the risk factors associated with the need for high-dose budesonide (≥6mg/d) to maintain clinical remission.
RESULTS: Budesonide induced clinical remission in 92\% of patients, with good tolerance. Fourteen of 68 patients (21\%; 95\% CI, 13-32\%) needed high-dose budesonide to maintain remission. Only intake of NSAIDs at diagnosis (OR, 8.6; 95\% CI, 1.6-44) was associated with the need for high-dose budesonide in the multivariate analysis.
TREATMENT: with thiopurines was effective in 5 out of 6 patients (83\%; 95\% CI, 44-97\%), allowing for withdrawal from or a dose decrease of budesonide.
CONCLUSIONS: One fifth of CC patients, especially those with NSAID intake at diagnosis, require high-dose budesonide (≥6mg/d) to maintain clinical remission. In this setting, thiopurines might be effective as budesonide-sparing drugs.},
	language = {eng},
	number = {9},
	journal = {Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
	author = {Fernandez-Bañares, Fernando and Piqueras, Marta and Guagnozzi, Danila and Robles, Virginia and Ruiz-Cerulla, Alexandra and Casanova, María José and Gisbert, Javier P. and Busquets, David and Arguedas, Yolanda and Pérez-Aisa, Angeles and Fernández-Salazar, Luis and Lucendo, Alfredo J. and {GECM (Grupo Español de Colitis Microscópica)}},
	year = {2017},
	pmid = {28457904},
	keywords = {Article, Azathioprine, Budesonide, Collagenous colitis, Digestiu, Maintenance therapy},
	pages = {973--977},
}

{"_id":"n8DjZJgy86BfgBgtr","bibbaseid":"fernandezbaares-piqueras-guagnozzi-robles-ruizcerulla-casanova-gisbert-busquets-etal-collagenouscolitisrequirementforhighdosebudesonideasmaintenancetreatment-2017","downloads":0,"creationDate":"2018-10-11T03:50:31.097Z","title":"Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment","author_short":["Fernandez-Bañares, F.","Piqueras, M.","Guagnozzi, D.","Robles, V.","Ruiz-Cerulla, A.","Casanova, M. J.","Gisbert, J. P.","Busquets, D.","Arguedas, Y.","Pérez-Aisa, A.","Fernández-Salazar, L.","Lucendo, A. J.","GECM (Grupo Español de Colitis Microscópica)"],"year":2017,"bibtype":"article","biburl":"https://bibbase.org/zotero/Bibliotecacst","bibdata":{"bibtype":"article","type":"article","title":"Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment","volume":"49","issn":"1878-3562","shorttitle":"Collagenous colitis","doi":"10.1016/j.dld.2017.03.026","abstract":"BACKGROUND: Controlled studies show high efficacy of budesonide in inducing short-term clinical remission in collagenous colitis (CC), but relapses are common after its withdrawal. AIM: To evaluate the need for high-dose budesonide (≥6mg/d) to maintain clinical remission in CC. METHODS: Analysis of a multicentre retrospective cohort of 75 patients with CC (62.3±1.5years; 85% women) treated with budesonide in a clinical practice setting between 2013 and 2015. Frequency of budesonide (9mg/d) refractoriness and safety, and the need for high-dose budesonide to maintain clinical remission, were evaluated. Drugs used as budesonide-sparing, including azathioprine and mercaptopurine, were recorded. Logistic regression analysis was performed to evaluate the risk factors associated with the need for high-dose budesonide (≥6mg/d) to maintain clinical remission. RESULTS: Budesonide induced clinical remission in 92% of patients, with good tolerance. Fourteen of 68 patients (21%; 95% CI, 13-32%) needed high-dose budesonide to maintain remission. Only intake of NSAIDs at diagnosis (OR, 8.6; 95% CI, 1.6-44) was associated with the need for high-dose budesonide in the multivariate analysis. TREATMENT: with thiopurines was effective in 5 out of 6 patients (83%; 95% CI, 44-97%), allowing for withdrawal from or a dose decrease of budesonide. CONCLUSIONS: One fifth of CC patients, especially those with NSAID intake at diagnosis, require high-dose budesonide (≥6mg/d) to maintain clinical remission. In this setting, thiopurines might be effective as budesonide-sparing drugs.","language":"eng","number":"9","journal":"Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","author":[{"propositions":[],"lastnames":["Fernandez-Bañares"],"firstnames":["Fernando"],"suffixes":[]},{"propositions":[],"lastnames":["Piqueras"],"firstnames":["Marta"],"suffixes":[]},{"propositions":[],"lastnames":["Guagnozzi"],"firstnames":["Danila"],"suffixes":[]},{"propositions":[],"lastnames":["Robles"],"firstnames":["Virginia"],"suffixes":[]},{"propositions":[],"lastnames":["Ruiz-Cerulla"],"firstnames":["Alexandra"],"suffixes":[]},{"propositions":[],"lastnames":["Casanova"],"firstnames":["María","José"],"suffixes":[]},{"propositions":[],"lastnames":["Gisbert"],"firstnames":["Javier","P."],"suffixes":[]},{"propositions":[],"lastnames":["Busquets"],"firstnames":["David"],"suffixes":[]},{"propositions":[],"lastnames":["Arguedas"],"firstnames":["Yolanda"],"suffixes":[]},{"propositions":[],"lastnames":["Pérez-Aisa"],"firstnames":["Angeles"],"suffixes":[]},{"propositions":[],"lastnames":["Fernández-Salazar"],"firstnames":["Luis"],"suffixes":[]},{"propositions":[],"lastnames":["Lucendo"],"firstnames":["Alfredo","J."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["GECM (Grupo Español de Colitis Microscópica)"],"suffixes":[]}],"year":"2017","pmid":"28457904","keywords":"Article, Azathioprine, Budesonide, Collagenous colitis, Digestiu, Maintenance therapy","pages":"973–977","bibtex":"@article{fernandez-banares_collagenous_2017,\n\ttitle = {Collagenous colitis: {Requirement} for high-dose budesonide as maintenance treatment},\n\tvolume = {49},\n\tissn = {1878-3562},\n\tshorttitle = {Collagenous colitis},\n\tdoi = {10.1016/j.dld.2017.03.026},\n\tabstract = {BACKGROUND: Controlled studies show high efficacy of budesonide in inducing short-term clinical remission in collagenous colitis (CC), but relapses are common after its withdrawal.\nAIM: To evaluate the need for high-dose budesonide (≥6mg/d) to maintain clinical remission in CC.\nMETHODS: Analysis of a multicentre retrospective cohort of 75 patients with CC (62.3±1.5years; 85\\% women) treated with budesonide in a clinical practice setting between 2013 and 2015. Frequency of budesonide (9mg/d) refractoriness and safety, and the need for high-dose budesonide to maintain clinical remission, were evaluated. Drugs used as budesonide-sparing, including azathioprine and mercaptopurine, were recorded. Logistic regression analysis was performed to evaluate the risk factors associated with the need for high-dose budesonide (≥6mg/d) to maintain clinical remission.\nRESULTS: Budesonide induced clinical remission in 92\\% of patients, with good tolerance. Fourteen of 68 patients (21\\%; 95\\% CI, 13-32\\%) needed high-dose budesonide to maintain remission. Only intake of NSAIDs at diagnosis (OR, 8.6; 95\\% CI, 1.6-44) was associated with the need for high-dose budesonide in the multivariate analysis.\nTREATMENT: with thiopurines was effective in 5 out of 6 patients (83\\%; 95\\% CI, 44-97\\%), allowing for withdrawal from or a dose decrease of budesonide.\nCONCLUSIONS: One fifth of CC patients, especially those with NSAID intake at diagnosis, require high-dose budesonide (≥6mg/d) to maintain clinical remission. In this setting, thiopurines might be effective as budesonide-sparing drugs.},\n\tlanguage = {eng},\n\tnumber = {9},\n\tjournal = {Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},\n\tauthor = {Fernandez-Bañares, Fernando and Piqueras, Marta and Guagnozzi, Danila and Robles, Virginia and Ruiz-Cerulla, Alexandra and Casanova, María José and Gisbert, Javier P. and Busquets, David and Arguedas, Yolanda and Pérez-Aisa, Angeles and Fernández-Salazar, Luis and Lucendo, Alfredo J. and {GECM (Grupo Español de Colitis Microscópica)}},\n\tyear = {2017},\n\tpmid = {28457904},\n\tkeywords = {Article, Azathioprine, Budesonide, Collagenous colitis, Digestiu, Maintenance therapy},\n\tpages = {973--977},\n}\n\n","author_short":["Fernandez-Bañares, F.","Piqueras, M.","Guagnozzi, D.","Robles, V.","Ruiz-Cerulla, A.","Casanova, M. J.","Gisbert, J. P.","Busquets, D.","Arguedas, Y.","Pérez-Aisa, A.","Fernández-Salazar, L.","Lucendo, A. J.","GECM (Grupo Español de Colitis Microscópica)"],"key":"fernandez-banares_collagenous_2017","id":"fernandez-banares_collagenous_2017","bibbaseid":"fernandezbaares-piqueras-guagnozzi-robles-ruizcerulla-casanova-gisbert-busquets-etal-collagenouscolitisrequirementforhighdosebudesonideasmaintenancetreatment-2017","role":"author","urls":{},"keyword":["Article","Azathioprine","Budesonide","Collagenous colitis","Digestiu","Maintenance therapy"],"downloads":0,"html":"","metadata":{"authorlinks":{}}},"search_terms":["collagenous","colitis","requirement","high","dose","budesonide","maintenance","treatment","fernandez-bañares","piqueras","guagnozzi","robles","ruiz-cerulla","casanova","gisbert","busquets","arguedas","pérez-aisa","fernández-salazar","lucendo","gecm (grupo español de colitis microscópica)"],"keywords":["article","azathioprine","budesonide","collagenous colitis","digestiu","maintenance therapy"],"authorIDs":[],"dataSources":["TR9pX4mH5rDPr29Zo"]}